Leading contract research organisation (CRO) Cellomatics Biosciences has moved into new purpose-built premises in Nottingham in the wake of rising demand for its bespoke preclinical and early drug discovery phase laboratory services.
The company’s new facilities in Colwick, Nottingham represent a three-fold increase in the company’s footprint, allowing room for further expansion. The purpose-built facility is an independent building covering approximately 5,500 sq ft of space across two levels. The ground floor is dedicated to laboratory facilities, whilst the first floor provides scientific…
The ‘Invest USA’ events program is the launch pad that supports UK & European companies seeking to invest in the USA.
We assist in gaining direct access to the right independent advisors and partners to successfully enter the USA. We take out the hassle and support you every step of the way for sustainable success. A trusted, experienced team to assist you through your USA journey.
Each brief we receive is treated as a bespoke solution and our deliverables are customised
and tailored to your needs.
The Invest USA program covers services such as;
Board…
Cambridge, UK, 13 June 2022:
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
Colin brings over 20 years’ experience in commercial and business development roles. Prior to joining Evonetix he was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where…
Analysis Published by PrecisionLife Reveals Potential to Systematically Reposition Hundreds of Patented Drugs into New Indications to Address Unmet Medical Needs
• PrecisionLife’s unique combinatorial analytics approach to understanding the drivers of disease biology in patient subgroups has revealed hundreds of new commercial opportunities to reposition patented drugs and drug candidates into novel indications, with significant near-term additional revenue potential for pharmaceutical companies
• Careful indication extension or repositioning of drugs coupled with patient stratification…
AMSBIO has expanded its range of top quality, high-performance assay kits, antibodies, enzymes, and substrates for cellular metabolism research.
Cell metabolism is the series of chemical synthesis (Anabolism) and degradation (Catabolism) reactions of complex macromolecules, catalyzed by enzymes that take place in living organisms to sustain those organisms. Anabolism uses energy to make macromolecules (sugars, fatty acids, amino acids) and biomolecular polymers (polysaccharides, lipids, proteins). Catabolism releases energy when these are broken down into smaller molecules (carbon dioxide,…
The Enterprise Strategy from Anglia Innovation Partnership LLP will kickstart investment into new businesses at Norwich Research Park.
Anglia Innovation Partnership LLP, the organisation that manages Norwich Research Park, has launched its Enterprise Strategy to kickstart investment into new businesses at the Park.
Its aim is two-fold: to encourage those with a potential idea for a business – be they entrepreneurs or people studying or working at the Park – to come forward for support. It will also highlight to investors – whether venture capital companies or high net worth individuals – the…
Presenters will explain how long-term and whole-cell hepatocyte models can be used to improve in-vitro in-vivo correlation predictions and advance drug discovery and development research
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it will host a symposium entitled “Innovative Models for ADME-Tox Research” at Hotel Odelya in Basel, Switzerland on June 22.
“We are delighted to have this opportunity to meet with our biopharmaceutical colleagues in person,” said Jeremy Clarke, Senior Director of Business…
Polyspecific antibodies for cancer research
AMSBIO announce a new range of high-quality bispecific antibodies (BsAbs) and trispecific antibodies (TsAbs) that can used to provide enhanced cancer therapeutic efficacy and/or safety compared to what can be achieved with conventional monospecific antibodies.
The concept of using a molecule with more than one binding site to enhance its biological function has been around for some time. Polyspecific antibodies are the basis of a new class of anti-cancer agents which offer the potential to be directed at multiple tumor antigens to eradicate tumor…
AMSBIO offer an extensive range of aptamers targeting many human proteins linked to cancer. Aptamers bind to target molecules with the same affinity and specificity as antibodies but offer significant advantages, in particular a lack of immunogenicity, which makes them an ideal tool for cancer diagnosis and therapy.
There are two major applications for aptamers in cancer therapy. Aptamers can be used as antagonists by targeting and inhibiting cancer-specific molecules. They can also be used as delivery vehicles for therapeutics by specifically targeting cell membrane receptors on cancer cells…
AMSBIO announce the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications.
Continued expansion of cell therapy applications across healthcare and the life sciences is driving a rapidly increasing need for clinically applicable ancillary materials. A key requirement is for recombinant proteins, such as growth factors and cytokines. This demand for clinically applicable recombinant proteins places stringent requirements on product quality, lot-to-lot consistency, and compliance with all relevant laws and regulations.
All StemFit…